NOTE: Serious adverse reactions in patients following a prophylactic dose of mefloquine should be reported to the Centers for Disease Control and Prevention (CDC) Malaria Section 770—488—7760.posted by klangklangston at 11:44 AM on December 2, 2010 [4 favorites]
The most frequently observed adverse experience with mefloquine therapy is nausea/vomiting (3%). Other frequently reported (>= 1% of patients) adverse reactions during therapy with mefloquine include abdominal pain, anorexia, and diarrhea. Dyspepsia has also been noted.
Skin rash (unspecified) is reported in > 1% of patients on mefloquine. Other infrequently reported adverse events include alopecia, pruritus, and urticaria, and telogen effluvium (loss of resting hair). Stevens-Johnson Syndrome and erythema multiforme have also been reported with mefloquine therapy, however, serious adverse reactions to mefloquine therapy have been rarely reported and may be difficult to distinguish from the symptoms of acute malaria infection.
Frequently reported (>= 1% of patients) adverse reactions during therapy with mefloquine include vestibular disorders such as tinnitus and hearing impairment.
Neuropsychiatric events occur in roughly 1 out of 10,000 users of mefloquine and include vertigo, visual impairment, and central nervous system disturbances. Occasionally, more severe neuropsychiatric disorders have been reported such as seizures, syncope, sensory and motor neuropathies (including paresthesias, tremor and ataxia), agitation or restlessness, aggression, anxiety, confusion, depression, encephalopathy, forgetfulness, hallucinations, insomnia, mood changes/mood swings, emotional lability, nightmares, panic attacks, and psychosis or paranoid reactions. Rare cases of suicidal ideation and suicide have been reported though no relationship to drug administration has been confirmed. In post-marketing data, vertigo, dizziness, memory impairment, and loss of balance have been reported to continue for months after mefloquine has been discontinued. Headache has also been noted in > 1% of patients.[28301]
QT prolongation has been reported when mefloquine is used in combination with certain other drugs such as halofantrine (see Drug Interactions). Post-marketing cardiovascular adverse reactions include chest pain (unspecified), hypertension, hypotension, palpitations, sinus tachycardia, first degree AV block, ECG changes, irregular heart rate, and extrasystoles have been noted in >= 1% of patients, while sinus bradycardia is seen in <>= 1% of patients using mefloquine include arthralgia or myalgia, chills, fatigue, and fever. Asthenia has been reported in <>
Noting all that, this does seem like a bit of wolf-crying over "MKULTRA mind control," as Truth-Out alluded. More prisoners likely got tinnitus.
« Older In today's example of kids smarter than you and I,... | Rhys Millen drifting his 750-h... Newer »
This thread has been archived and is closed to new comments
posted by Chocolate Pickle at 8:30 AM on December 2, 2010 [5 favorites]